AscellaHealth Achieves Favorable Ranking Among Prestigious 2022 Inc. Magazine’s 5000 Honorees: The Most Successful Companies in America For Second Consecutive Year

BERWYN, Pa.–(BUSINESS WIRE)–AscellaHealth, a global healthcare and specialty pharmacy solutions company, has placed in the top one third on the annual Inc. 5000 list, the most prestigious ranking of the nation’s fastest-growing private companies. “Making the Inc. 5000 list for the second year in a row with a 317% three-year revenue growth is a significant … [Read more…]

Global 3D Printed Drugs Market Report 2022: Surge in Demand for Instantaneous Soluble Drugs & Increasing Use of 3D Printing Technique in the Medical & Healthcare Industries Drive Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “3D Printed Drugs Market Research Report by Technology (Direct-Write, Fused Deposition Modelling, and Inkjet Printing), End User, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering. The Global 3D Printed Drugs Market size was estimated at … [Read more…]

Blessing Health targets smarter sepsis surveillance with Wolters Kluwer

POC Advisor’s real-time monitoring detects sepsis 6 hours earlier and guides the right clinical decisions WALTHAM, Mass.–(BUSINESS WIRE)–Each year in the United States, sepsis accounts for 270,000 deaths and costs nearly $27 billion — making it one of the largest cost drivers for U.S. hospitals.1 To quickly identify and best care for patients with sepsis … [Read more…]

Dr. Jeffrey Gudin, Chief Medical Officer of Virpax Pharmaceuticals, to Present Poster at World Congress of World Institute of Pain

BERWYN, Pa.–(BUSINESS WIRE)–#pharma—Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that Jeffrey Gudin, MD, will present a poster at the World Congress of World Institute of Pain entitled, “Enkephalin as … [Read more…]

Research Provides New Insight into ALS

Tisch MS Research Center of New York identifies key protein that causes motor disability and motor neuron degeneration in sALS, paving the way for first-of-its-kind treatment target for the disease NEW YORK–(BUSINESS WIRE)–The Larry G. Gluck Division of ALS Research, located at the Tisch MS Research Center of New York, has published research in Brain … [Read more…]

ValenzaBio Appoints Industry Veteran Peter Greenleaf to its Board of Directors

BETHESDA, Md.–(BUSINESS WIRE)–ValenzaBio, Inc., a biopharmaceutical company developing monoclonal antibody (mAb) therapeutics for autoimmune and inflammatory indications, today announced the appointment of Peter Greenleaf to its board of directors. Mr. Greenleaf, a seasoned industry executive with nearly 30 years of experience leading successful life sciences companies, is currently the president, chief executive officer and member … [Read more…]

Tachyon Receives IND Clearance from FDA to Develop Novel KDM4 Inhibitor TACH101 for Advanced Solid Tumors

HOUSTON–(BUSINESS WIRE)–Tachyon Therapeutics, Inc. (“Tachyon” or “the Company”), a private biotechnology company developing transformative cancer therapies against novel targets, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to develop TACH101 for the treatment of advanced solid tumors. “The approval of this IND marks a … [Read more…]

Bacterial Biofilms, Responsible for Up to 75% of All Infectious Diseases in America, Explored in New Webinar From Quidel Corporation

SAN DIEGO–(BUSINESS WIRE)–#LymeDisease–The National Institutes of Health reports that bacterial biofilms are responsible for up to 75% of all infectious diseases in humans, including infections of wounds, the lungs and the urinary tract. This important medical reality is now being addressed in a new webinar made available by Quidel Corporation, the California-based diagnostic health care … [Read more…]

Ranok Therapeutics Announces Initiation of Patient Dosing in a Phase 1/2 Clinical Trial of RNK05047, a First-in-Class BRD4-Targeting CHAMP™ Protein Degrader

Study will evaluate the first protein degrader developed using Ranok’s innovative CHAMP™ technology in patients with advanced solid tumors or diffuse large B-cell lymphoma (DLBCL) BOSTON & HANGZHOU, China–(BUSINESS WIRE)–Ranok Therapeutics, a clinical-stage biopharmaceutical company that is developing a novel approach to targeted protein degradation for the treatment of cancer and other serious diseases, today … [Read more…]

Glaukos Announces Participation in the Wells Fargo Healthcare Conference

ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 7, 2022, at 3:45 p.m. ET in Boston, MA. … [Read more…]